• Goldman Sachs increased Wells Fargo & Company WFC Price target from $46 to $48. Goldman Sachs analyst Richard Ramsden has upgraded the stock to buy from neutral. Wells Fargo shares are up 1.1% in premarket trading at $40.68.
• Baird further lowered the price target Intercept Pharmaceuticals, Inc. ICPT from $52 to $35. Baird analyst Brian Skorney kept an Outperform rating on the stock. Intercept Pharmaceuticals shares fell 15% to close at $13.95 on Friday.
• Mizuho cut sempra SRE Price target from $173 to $161. Mizuho analyst Anthony Crowdell maintained a buy rating for the stock. Shares of Sempra fell 1% to close at $149.94 on Friday.
• B of A Securities lowered Livent Corporation LTHM Price target from $31 to $27. B of A Securities analyst Matthew DeYoe downgraded the stock to underperform from neutral. Livent is down 4% in premarket trading at $29.42.
• SVB Leerink cut Replimune Group, Inc. SUBSTITUTE Price target from $37 to $30. SVB Leerink analyst Jonathan Chang kept an Outperform rating on the stock. Replimune shares rose 3.9% to close at $17.27 on Friday.
• HC Wainwright & Co upgraded Axella Health Inc. AXLA Price target from $8 to $10. HC Wainwright & Co. analyst Ed Arce maintained the stock with a buy. Axcella Health shares fell 11.4% to close at $1.71 on Friday.

Watch this: US stock futures mixed after recording quarterly losses; Tesla in focus